<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20261011071394N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-05</date_registration>
      <primary_sponsor>University of Sistan and Baluchestan</primary_sponsor>
      <public_title>Adding Otago exercises to trunk exercises in women with Parkinson’s disease</public_title>
      <acronym></acronym>
      <scientific_title>The effect of adding Otago exercises to trunk exercises on motor assessment, freezing of gait, balance, position sense, lower extremity muscle quality index in middle-aged women with Parkinson's disease</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-12-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/94173</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, 60 eligible patients will be recruited using convenience and purposive sampling. To control for the potential effect of disease severity and ensure a balanced distribution across the study groups, participants will be stratified into three categories according to disease stage, based on the Hoehn and Yahr scale (stages 1, 2, and 3), after enrollment and before group allocation.

Subsequently, participants will be allocated to four study groups using stratified permuted block randomization, with an allocation ratio of 1:1:1:1. Separate random allocation sequences will be generated for each of the three strata using blocks of four, such that within each block, one participant will be assigned to each of the four study groups.

The random allocation sequences will be generated using the Randomization.com website by an independent researcher who will not be involved in participant recruitment or assessment. This method will be used to promote balance in the number of participants across the study groups and to control for the distribution of disease severity, Blinding description: All outcome assessments will be performed by a single assessor who will remain blinded to the group allocation of each participant throughout the study.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Parkinson.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Otago Exercises , Participants in this group will perform the Otago exercise program three times per week during the intervention period. Intervention 2: Intervention group: Trunk Exercises , Participants in this group will perform trunk exercises three times per week during the intervention period. Intervention 3: Intervention group: Combined Otago and Trunk Exercises ,Participants in this group will perform a combined exercise program consisting of Otago exercises and trunk exercises three times per week during the intervention period. Intervention 4: Control group: Participants in the control group will not receive any exercise intervention during the study period and will continue their usual daily activities and prescribed medical treatment.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The decision regarding sharing de-identified individual participant data will depend on the assessment of ethical considerations, confidentiality requirements, and data availability after the completion of the study.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mansore Golbou</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alley No. 3, Sardaran Street</address>
        <city>Neyriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7491647963</zip>
        <telephone>007153837266</telephone>
        <email>mansore.golbou@gmail.com</email>
        <affiliation>University of Sistan and Baluchestan</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mansore Golbou</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alley No. 3, Sardaran Street</address>
        <city>Neyriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7491647963</zip>
        <telephone>+98 71 5383 7266</telephone>
        <email>mansore.golbou@gmail.com</email>
        <affiliation>University of Sistan and Baluchestan</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Female sex
Age range of 40 to 60 years.
Definite diagnosis of Parkinson’s disease made by a neurologist
Regular and stable use of prescribed Parkinson’s disease medications
Being in Hoehn and Yahr stages 1 to 3 of Parkinson’s disease
Absence of other neurological or musculoskeletal diseases</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>History of surgery or fractures involving bones or joints that limit physical function
Participation in physical rehabilitation programs during the study
Failure to attend training sessions (five non-consecutive sessions or three consecutive sessions)
Voluntary withdrawal from the study
Unstable cardiovascular diseases
Medical contraindications to exercise
History of deep brain stimulation (DBS) surgery for symptom management</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G20</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Parkinson's disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Otago Exercises , Participants in this group will perform the Otago exercise program three times per week during the intervention period.</i_keyword>
      <i_keyword>Intervention group: Trunk Exercises , Participants in this group will perform trunk exercises three times per week during the intervention period.</i_keyword>
      <i_keyword>Intervention group: Combined Otago and Trunk Exercises ,Participants in this group will perform a combined exercise program consisting of Otago exercises and trunk exercises three times per week during the intervention period.</i_keyword>
      <i_keyword>Control group: Participants in the control group will not receive any exercise intervention during the study period and will continue their usual daily activities and prescribed medical treatment.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Motor Assessment. Timepoint: At the beginning of the study (before the intervention began) and 12 weeks after the exercises. Method of measurement: Unified Parkinson’s Disease Rating Scale, Part III (Motor Examination).</prim_outcome>
      <prim_outcome>Freezing of Gait. Timepoint: At the beginning of the study (before the intervention began) and 12 weeks after the exercises. Method of measurement: New Freezing of Gait Questionnaire.</prim_outcome>
      <prim_outcome>Balance. Timepoint: At the beginning of the study (before the intervention began) and 12 weeks after the exercises. Method of measurement: Mini-Balance Evaluation Systems Test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Position Sense. Timepoint: At the beginning of the study (before the intervention began) and 12 weeks after the exercises. Method of measurement: Knee Joint Position Sense Assessment Using the Measure App on an iPhone.</sec_outcome>
      <sec_outcome>Lower Extremity Muscle Quality Index. Timepoint: At the beginning of the study (before the intervention began) and 12 weeks after the exercises. Method of measurement: The Lower Extremity Muscle Quality Index , will be calculated using the specific MQI formula based on performance in the Ten-Times Sit-to-Stand Test.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>University of Sistan and Baluchestan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-06-16</approval_date>
        <contact_name>University of Sistan and Balochestan</contact_name>
        <contact_address>University Street, University of Sistan and Baluchestan, Zahedan Sistan-va-Balouchestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
